A Long-term, Open-label Study to Evaluate the Safety and Efficacy of Orally Administered Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema
Latest Information Update: 07 Apr 2026
At a glance
- Drugs Deucrictibant (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions; Therapeutic Use
- Acronyms CHAPTER-4
- Sponsors Pharvaris
Most Recent Events
- 16 Mar 2026 Protocol has been amended(change in planned patient number and Change in the timeline of primary endpoint).
- 16 Mar 2026 Planned number of patients changed from 130 to 170.
- 12 Mar 2025 Status changed from not yet recruiting to recruiting.